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Abstract: Cell-penetrating peptides (CPPs) have long 
held great promise for the manipulation of living cells 
for therapeutic and research purposes. They allow a wide 
array of biomolecules from large, oligomeric proteins to 
nucleic acids and small molecules to rapidly and effi-
ciently traverse cytoplasmic membranes. With few excep-
tions, if a molecule can be associated with a CPP, it can 
be delivered into a cell. However, a growing realization in 
the field is that CPP-cargo fusions largely remain trapped 
in endosomes and are eventually targeted for degrada-
tion or recycling rather than released into the cytoplasm 
or trafficked to a desired subcellular destination. This 
‘endosomal escape problem’ has confounded efforts to 
develop CPP-based delivery methods for drugs, enzymes, 
plasmids, etc. This review provides a brief history of CPP 
research and discusses current issues in the field with 
a primary focus on the endosomal escape problem, for 
which several promising potential solutions have been 
developed. Are we on the verge of developing technolo-
gies to deliver therapeutics such as siRNA, CRISPR/Cas 
complexes and others that are currently failing because 
of an inability to get into cells, or are we just chasing after 
another promising but unworkable technology? We make 
the case for optimism.
Keywords: cell-penetrating peptides; endocytosis; endo-
somal escape; protein transduction domains; TAT.
Introduction
Nearly 30 years ago, HIV researchers Frankel and Green 
(1, 2) independently stumbled upon a phenomenon that 
ultimately gave rise to a potentially transformative techno-
logy: the HIV protein transactivator of transcription (TAT) 
could readily pass through the plasma membrane of unin-
fected mammalian cells. Further, and most importantly, 
TAT retained its normal functionality and subcellular 
localization post-entry as it readily entered the nucleus 
and promoted gene transcription. This surprising ability 
to traverse the cellular membrane was later mapped to a 
stretch of 12 basic amino acids and this penetrative prop-
erty could be conferred onto other proteins to which that 
sequence was fused (3, 4). A new area of intense scientific 
research was thus born: the delivery of bioactive mole-
cules into mammalian cells via direct penetration of the 
plasma membrane.
Since Frankel’s and Green’s discoveries, a large 
number of peptides that are rapidly internalized and 
enable transport of macromolecular cargos into mam-
malian cells in vitro and in vivo have been discovered or 
designed. These peptides came to be known as cell-pen-
etrating peptides (CPPs, also frequently referred to as 
protein transduction domains, or PTDs). The term CPP 
now refers to a broad grouping of non-homologous short 
peptides, the majority of which are hydrophilic and cati-
onic in nature, though amphiphilic, anionic and hydro-
phobic CPPs have been reported. A database of more than 
1600 CPPs is described by Agrawal et al. (5). Their unify-
ing property is the ability to penetrate the plasma mem-
brane for delivery of cargo into cells, from peptides and 
proteins, both small and large, to various nucleic acids, 
including DNA, RNA, small interfering RNAs (siRNAs) and 
peptide-nucleic acids (PNAs) (6–9).
Thirty years later, CPP-based technologies have 
largely failed. Frankel and Pabo (1) first reported that 
cellular entry of TAT was likely via an endosomal-inde-
pendent mechanism as introduction of the endosomal-
blocking agent chloroquine enhanced TAT uptake into 
cells. However, much of the subsequent data supporting 
spontaneous membrane translocation were found to be 
*Corresponding author: Jonathan L. McMurry, Department of 
Molecular and Cellular Biology, Kennesaw State University, 
370 Paulding Ave NW, MD 1201, Kennesaw, GA 30144, USA, 
e-mail: jmcmurr1@kennesaw.edu
Julia C. LeCher and Scott J. Nowak: Department of Molecular and 
Cellular Biology, Kennesaw State University, 370 Paulding Ave NW, 
MD 1201, Kennesaw, GA 30144, USA
Brought to you by | Kennesaw State University
Authenticated
Download Date | 7/3/18 4:02 PM
132      J.C. LeCher et al.: Cell-penetrating peptides and the endosomal escape problem
the result of experimental artifacts. It was soon realized 
that majority of CPPs became trapped in endosomes fol-
lowing delivery into cells and, as a result, any associated 
cargo became trapped as well (10, 11). It is likely the case 
that, owing to endosomal entrapment, the vast majority 
of CPP cargos are eventually targeted to either the lyso-
some for degradation or back to the plasma membrane for 
recycling and subsequent ejection from the cell. We have 
dubbed this the ‘endosomal escape problem’.
In spite of setbacks, CPPs still have significant thera-
peutic and investigative potential. Currently, more than 25 
CPP clinical trials are underway, including a Phase III (12, 
13). To successfully transition CPP-based technology into 
therapeutic delivery systems, several considerations need 
to be made. This review focuses on fundamental questions 
and the challenges faced by the field in this endeavor: 
How do CPPs get into the cell? Once inside, how is cargo 
released from the endosome into the cytosol? How do we 
ensure biological activity and correct subcellular localiza-
tion of cargo following endosomal release? And finally, 
how can we ensure specificity in cellular targeting?
Breaking in: mechanisms of cellular 
entry
Currently, the field recognizes endocytosis to be the 
primary mode of CPP cellular entry and subsequent endo-
somal escape, the rate-limiting step for the effectiveness 
of CPPs to deliver cargo into living cells. However, there 
is still much controversy on how CPPs enter cells. In this 
section of the review, we will provide a brief history of 
30 years of mechanistic insight on CPP cellular entry with 
a primary focus on endocytosis.
A brief glance at endocytic pathways
Endocytosis is a broad term encompassing a variety of 
pathways utilized by the cell to bring outside molecules 
in for a multitude of purposes – receptor and lipid recy-
cling, inhibition of signal transduction, uptake of solutes/
nutrients and destruction of foreign/unwanted materials. 
The unifying property of endocytic pathways is, simply 
put, engagement of the plasma membrane for the forma-
tion of an intracellular membrane-bound organelle which 
will then transport the molecules to some destination 
within the cell. It is a tightly coordinated, energy-depend-
ent process requiring extensive cellular adaptors and 
cytoskeletal rearrangements. As illustrated in Figure  1, 
following organelle formation, an endocytic vesicle 
undergoes a pH-dependent maturation process as it tran-
sitions from the early sorting endosome (pH ~6–6.5) into 
the late endosome or multivesicular body (MVB; pH ~5). 
The acidification process is dependent on ionic gradients, 
requiring calcium, sodium and potassium efflux as well 
as hydrogen and chloride influx. An endosome has three 
potential fates – it may be targeted to the lysosome from 
the MVB for destruction of its intraluminal contents or its 
contents may be recycled back to the plasma membrane 
either directly from the sorting endosome or after routing 
from the MVB to the trans-Golgi network. Alternatively, 
some endosomal contents such as nutrients are needed 
by the cell and, thus, must be released into the cytosol. 
This latter process is mediated by the formation of intralu-
minal vesicles (ILVs) inside the endosome, essentially the 
formation of an exosome within the endosome. The ILV 
then undergoes a process known as ‘backfusion’ where it 
fuses with the endosomal membrane and its contents are 
released into the cytosol.
Endocytosis can further be broken down into phago-
cytosis and pinocytosis depending on whether entry is 
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Figure 1: An overview of endocytosis.
Endosome formation may be receptor (clathrin/caveolin) or 
non-receptor mediated (macropinocytosis). Following invagina-
tion (clathrin/cavaeolin) or evagination (macropinocytosis) of the 
plasma membrane, an early endosome is formed (1). As the endo-
some travels into the cell, it transitions to an early endosome and 
becomes increasingly acidified by pumping in cytosolic hydrogen 
ions into the vesicular lumen (2). As the early endosome matures, it 
begins to sort cargo by the formation of multiple smaller intralumi-
nal vesicles (ILVs) (3). Some of these vesicles may re-fuse with the 
endosomal membrane and deliver contents directly into the cytosol, 
called ‘backfusion’ while others will be destined for either the lyso-
some (4) or the trans-Golgi network (TGN) (5). Cargo delivered to the 
lysosome will be degraded while cargo delivered to the TGN will be 
recycled back to the plasma membrane. Some receptors can bypass 
the TGN and be directly recycled back to the plasma membrane from 
the early endosome (6).
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fluid phase or not. We will limit our discussion to pino-
cytic pathways most commonly engaged by CPPs – macro-
pinocytosis, clathrin-dependent and caveolin-dependent 
endocytosis and lipid-raft endocytosis. A full description 
of these pathways is outside the scope of this review; 
however, a brief description of these pathways is provided 
below:
1. Macropinocytosis is defined as a receptor-independ-
ent and coat-independent process. First described by 
Warren Lewis in 1931, this is a form of cellular ‘pino’ 
(drinking) ‘cytosis’ (14). Macropinocytosis is classi-
cally thought to be a non-specific mechanism to bring 
solutes/nutrients into the cell via large endocytic vesi-
cles. However, more recent studies point to a need for 
stimulation at the plasma membrane via the presence 
of extracellular growth factors [reviewed in Ref. (15)]. 
Further, different cell types may utilize this process in 
different ways given their particular needs. For exam-
ple, some cells use this process to obtain nutrients or 
to recycle portions of their membranes while immune 
cells utilize macropinocytosis for the regulation of 
antigen presentation.
2. Clathrin-dependent endocytosis is a receptor-driven 
process that results in the formation of a ‘coated’ vesi-
cle. The trimeric coat protein, clathrin, for which this 
pathway is defined, was the first coat protein to be iso-
lated from cellular membrane-bound vesicles in 1976 
by Pearse (16). During endocytosis, three-footed tris-
kelion subunits assemble via adaptor proteins at cho-
lesterol-deficient regions of the plasma membrane, 
forming into a lattice work to create a highly ordered 
‘caged’ structure which is internalized. This pathway 
is considered ubiquitous across all cell types and is 
utilized in a variety of ways; transferrins, low-density 
lipoproteins, hormones and neurotransmitters (dur-
ing reuptake) are a few examples of molecules taken 
up by this pathway.
3. Caveolin-mediated entry shares both similarities and 
distinctions from clathrin-mediated entry. Caveolins 
are also coat proteins that form tight associations 
with cholesterol present in the plasma membrane. 
Unlike the trimeric clathrins, following recruitment to 
the plasma membrane, caveolins form a distinct ‘U’ 
shape, with both N- and C-termini pointing toward 
the cytoplasm. The resulting invaginations resemble 
cave-like structures called caveolae, for which they 
were originally named (17). Not surprisingly, caveo-
lins are found localized to cholesterol-rich lipid rafts. 
Many growth factors utilize this pathway, as do some 
pathogens. Further, caveolin-dependent endocytosis 
is important in transendothelial transport. Unlike the 
more ubiquitous mechanism of clathrin-dependent 
endocytosis, caveolae formation is impacted by many 
cellular factors such as cell type as well as cell cycle 
progression. Further, some cells express caveolins at 
low levels or not at all.
4. Lipid raft endocytosis is a non-receptor-mediated, 
concentration-dependent form of endocytosis occur-
ring at cholesterol-enriched lipid rafts in the plasma 
membrane but does not rely on caveolin coat for-
mation. In this form of endocytosis, glycosylphos-
phatidylinositol-anchored proteins (GPI-AP) group 
into distinct microdomains, invaginate and form 
GPI-enriched intracellular vesicles. This pathway is 
primarily used as a constitutive means of bringing 
in extracellular fluids through lipid-raft-mediated 
pathways based in membrane-molecule interactions 
and has been described for SV40-virions, vitamins, 
GPI-binding proteins, MHC-class I, IL-2 and IgE. Even 
though these pathways show significant variability 
for the requirement of local mediators and in cargo 
fate (recycling, degradation, intracellular release), 
they share commonalities in that they are receptor-
mediated and proceed via an absorptive fluid-phase 
mechanism [reviewed in Ref. (18)].
Breaking in via endocytosis: 
the case and conundrum
Individual CPPs may engage one or more of the forms of 
pinocytosis defined above. With regard to TAT, different 
groups have reported cellular uptake by all of these endo-
cytic mechanisms (19–25). Further, some CPPs such as 
the well-studied arginine-rich, 16-residue peptide corre-
sponding to the third helix of the Drosophila melanogaster 
transcription factor Antennapedia homeodomain (Antp; 
penetratin) may enter via direct penetration (26). The 
debate is ongoing; CPP entry mechanism(s) is a heavily 
explored area with minimal consensus. Much of this likely 
owes to differences in laboratories, cell types, CPP con-
structs and experimental conditions.
Frankel and Pabo (1) demonstrated in their seminal 
paper that lysotrophic agents enhanced instead of block-
ing full-length TAT uptake into cells. This gave rise to the 
direct penetrance hypothesis that was rapidly embraced 
by many in the field. Three years later, Mann and Frankel 
(27) provided data that full-length TAT likely entered 
via an undefined absorptive-phase endocytic pathway. 
Namely, they found that uptake was significantly reduced 
when performed at 4°C (energy independent) compared 
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with 37°C. Interestingly, this was a cell-dependent effect 
as cervical cancer-derived cells (HeLa) showed a striking 
difference in energy-dependent uptake while temperature 
reduction had a notably smaller, though similar, impact 
on a T cell-derived cell line (27). This was the first illustra-
tion of a cell-type effect on TAT uptake and these findings 
hinted at complexities with which we are still coming to 
grips, including the importance of cell-specific differences 
in CPP uptake.
The 1990s saw a flurry of reports of direct penetrance 
by CPPs. However, many of these observations were later 
found to be artifactual (10). In particular, Lundberg et al. 
(10) demonstrated that intracellular redistribution and 
dispersed cytoplasmic and nuclear distribution of CPPs 
resulted from cellular fixation, whereas live cell imaging 
experiments indicated a punctate (likely endosomal) dis-
tribution. More recent work utilizing live cell imaging has 
shown evidence for the potential of non-endocytic uptake 
of some CPP constructs, but these data are not without 
constraints on the concentration of the CPP and nature of 
the cargo (19, 28).
By the onset of the 21st century, over a decade from 
the initial reports of TAT’s ability to traverse the plasma 
membrane, multiple conflicting reports were published in 
support of one endocytic pathway over another engaged 
by TAT as well as those of other newly discovered CPPs, as 
outlined in Table 1. In 2007, Duchardt et al. (19) designed 
a series of experiments to clarify contradictory data on 
the use of endocytic pathways by CPPs that plagued the 
field. They studied concentration-dependent uptake 
mechanisms of three well-characterized cationic CPPs 
(penetratin, TAT and R9) employing specific endosomal 
pathway inhibitors and tracers. It was demonstrated that 
all three CPPs engaged multiple forms of endocytosis 
(clathrin-dependent, caveolin-dependent and macropi-
nocytosis) and that the concentration of the CPP played 
a role in determining the endocytic pathway that was 
used. While these data are seemingly at odds with pre-
vious work, many proteins, receptors and viruses make 
use of all of these forms of endocytosis. Further, while all 
of these pathways exhibit specificity, there exists a large 
degree of functional redundancy and crosstalk among 
them.
Ten years later much remains unresolved concerning 
how CPPs enter a cell. Even though endocytosis gained the 
limelight as the primary means of entry, direct penetrance 
still remains a distinct possibility and an active area of 
interest in the field. Determinants dictating CPP utiliza-
tion of one endocytic pathway over another, or bypassing 
the endosome entirely, are thought to be highly contextual 
and dependent on the nature of the CPP, concentration, 
receptor availability, media conditions and cell type. A 
Table 1: Experimental evidence for the use of different endocytic pathways by TAT in different cell lines.
Endocytic pathway   Cell line   Endocytic pathway inhibitorsa/tracers   Methodology
Macropinocytosis   Tex.Ioxp.EG (T-cells)   β-Cyclodextrin; nystatin; EIPA; cytochalasin D (23)   Flow cytometry, live cell imaging (23)
  Cos-7 (fibroblasts)   EIPA; cytochalasin D/RFP-labeled caveolin (23)   Live cell imaging (23)
  CHO   Dyamin knockdown/transferrin (23)   Immunohistochemistry (23)
  K562 (lymphoblasts)   ATP-depletion; EIPA (29)   Flow cytometry (29)
Clathrin-dependent   HeLa   Chlorpromazine; potassium reduction/transferrin (30)
Chlorpromazine (effective at high concentrations of TAT 
– 40 μm); EIPA; MβCD (19) 
  Flow cytometry (30)
Flow cytometry, live cell imaging (19)
  Jurkat T-cells   4°C Incubation; chlorpromazine; filipin; Eps15, dynamin 
and intersectin dominant-negative mutants (25)
  Radioactivity labeling, 
immunohistochemistry (25)
  CHO   Potassium reduction, nystatin/transferrin (30)   Flow cytometry (30)
Caveolin-dependent   HeLa   4°C Incubation/cholera toxin, transferrin, CFP-labeled 
caveolin (20)
Cytochalasin D, MβCD, 4°C incubation/transferrin, 
EEA-1, cholera toxin (24)
  Live cell imaging (20)
Live cell imaging, 
immunohistochemistry, reporter 
assays, flow cytometry (24)
  Cos-1 (fibroblasts)   Cytochalasin D, MβCD, 4°C incubation/caveloin-1 (24)   Flow cytometry, 
immunohistochemistry (24)
Lipid raft   Jurkat T-cells   Cytochalasin D, MβCD, 4°C incubation (24)   Flow cytometry, 
immunohistochemistry (24)
Undefined   PBM-MOs   ATP-depletion, 4°C incubation (30)   Flow cytometry (30)
  HUVEC   ATP-depletion, 4°C incubation (30)   Flow cytometry (30)
aInhibitors: macropinocytosis – EIPA; clathrin – cytochalasin D, chlorpromazine, potassium reduction; caveolin – flipin, β-cyclodextrin, 
nystatin; lipid raft-β-cyclodextrin, nystatin, potassium reduction.
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better understanding of the factors influencing one form 
of uptake over another in different target cells and tissues 
will be paramount in optimizing targeting, uptake and 
endosomal escape strategies to develop CPPs for effective 
cargo delivery in vivo and in vitro.
A receptor for CPPs?
Regardless if cellular entry is direct or endosomal, the 
CPP must initially come into contact with the plasma 
membrane to facilitate uptake. Thus, requirements for 
cellular entry are a primary question in the field. Cur-
rently, CPP-membrane interaction is thought to be gov-
erned by either non-specific electrostatic interactions or 
via ligand-receptor binding. Given that TAT, the proto-
typical CPP, is derived from a HIV protein, much of the 
work in this arena has been based on HIV research and 
has utilized either TAT or TAT-homologous arginine-rich 
CPPs.
Early work on HIV entry mechanisms revealed that 
full-length TAT could bind, among other molecules, 
ubiquitously expressed cellular proteoglycans (namely 
heparan sulfate proteoglycans, or HSPGs), integrins and 
chemokine (C-X-C motif) receptor 4 (CXCR4), though in the 
latter case it serves as an antagonist (31–36). All of these 
molecules readily activate endocytic pathways in both 
clathrin-dependent and -independent mechanisms. In 
particular, binding to HSPGs and integrins was mapped to 
the basic domain of TAT, which also confers its cell-pen-
etrating properties (31). In 1993, Vogel et al. (34) reported 
that while the basic domain of TAT could readily bind 
integrin αvβ5, antibodies blocking this interaction had no 
effect on TAT uptake into cells. Since these observations, 
HSPGs have received prominent attention as potential TAT 
receptors (29, 30, 33, 37–39).
Interaction between TAT’s basic domain (its CPP 
sequence) and heparan sulfates (HSs) was originally elu-
cidated by Rusnati et  al. (40). These observations were 
expanded upon in 2001 by Tyagi et al. (33) who provided 
evidence for the need for cell surface proteoglycans 
for cellular internalization of TAT constructs, as cells 
defective in glycosaminoglycan (GAG) synthesis showed 
reduced TAT uptake. Mounting evidence for the roles 
of HSPGs in uptake and endocytosis of arginine-rich 
CPPs such as TAT have provided a new framework for 
the study of receptor-mediated entry of CPPs (29, 30, 33, 
37–40). With respect to cationic CPPs, interactions with 
negatively charged GAGs comprising HSPGs are thought 
to concentrate these CPPs at the plasma membrane to 
facilitate endosomal uptake.
Expanding upon the HSPG-CPP interaction hypoth-
esis, Letoha et al. (29) in 2010 and Kawaguchi et al. (37) 
in 2016 identified the ubiquitous HSPG syndecan 4 as a 
potential receptor for the classical arginine-rich CPPs. 
Letoha et al. (29) reported that syndecan 4 enhanced the 
uptake of TAT, penetratin and the bioengineered octoar-
ginine peptide R8 via an energy-dependent endocytic 
mechanism they attributed to macropinocytosis. This is 
not surprising as syndecan 4 is known to activate multiple 
downstream small GTPases involved in different endocytic 
pathways including macropinocytosis, clathrin-depend-
ent and caveolin-dependent endocytosis as well as lipid 
raft-dependent endocytosis (41, 42). A major limitation to 
this work is the use of a cell-based overexpression system 
in lymphoblasts, which normally do not express synde-
cans. There is some doubt as to whether a cell that does 
not normally express this molecule will recreate normal 
syndecan-mediated cellular uptake pathways following 
transfection.
Kawaguchi et  al. (37) later performed a screen for 
binding partners of R8 in HeLa cells. They identified 17 
potential R8 binding partners, seven of which are pro-
teoglycans and two of which are core components of the 
extracellular matrix (ECM). They confirmed that synde-
can 4 facilitated cellular entry of R8 in a concentration-
dependent manner, as siRNA-mediated knockdown of 
syndecan 4 impacted uptake at a low concentration (1 μm), 
but only had little effect at a high concentration (10 μm) 
(37). In contrast to previous observations, R8 appeared 
to predominantly utilize a clathrin-dependent endocytic 
pathway instead of micropinocytosis though this may be a 
by-product of experimental conditions (22).
The other recently identified candidate receptor, 
CXCR4, is highly expressed on migratory cells such as 
immune and cancerous cells. CXCR4  was originally 
identified as a key receptor for HIV type X4 and works 
in concert with co-receptor CD4 and cell-surface HSPGs 
to facilitate viral entry into target cells (35, 36). In 2012, 
Tanaka et al. (43) provided evidence for the use of CXCR4 
followed by subsequent macropinocytosis by the argi-
nine-rich CPP R12. In support of CXCR4 and syndecan 
4  serving as receptors for arginine-rich CPPs, CXCR4 is 
normally complexed with syndecan 4 and that associa-
tion promotes binding of its natural ligand, stromal cell-
derived factor 1 (SDF-1) (44). At odds with this, however, 
Tanaka et  al. found that CXCR4 facilitated uptake of 
R12 but not the other arginine-rich CPPs, TAT or R8, the 
latter being the proposed receptor of syndecan 4 (37, 
43). The failure of TAT to bind CXCR4 likely owes to the 
fact that binding to CXCR4  has been mapped to TAT’s 
central ‘chemokine-like’ domain though direct analysis 
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of its basic domain binding to CXCR4 has not been per-
formed to our knowledge. Finally, CXCR4 is found in low 
abundance in normal, non-migratory, healthy cells and 
tissues; so, while CXCR4  may facilitate the uptake of at 
least one CPP, R12, as noted by the authors, it is likely not 
the sole receptor.
Identifying receptors for different CPPs will be para-
mount in untangling mechanisms of entry and may lead to 
the development of more efficient cargo-delivering CPPs. 
However, if CPPs can readily utilize more ubiquitously 
expressed molecules such as HSPGs, this may reduce the 
therapeutic value without effective targeting strategies. 
Further, failure to control endocytic pathway engagement 
means a variety of fates may await any given molecule 
every time it is introduced.
Busting out: escape from 
the endosome
The field has increasingly recognized that the principal 
roadblock to the development of therapeutics is cargo 
entrapment in the endocytic pathway (13, 45). Almost 
all described CPP technologies are reliant on covalent 
crosslinking or non-specific hydrophobic interactions 
(46). In our opinion, it is here that CPPs currently fail as 
a workable technology. If cellular entry is receptor medi-
ated, it could well be that the high affinity of the CPP for 
its receptor is in part due to low off rates and hence trap-
ping of its linked cargo in the endosomes may essentially 
be a kinetic problem. In this section, we focus on some of 
the more promising approaches that have been developed 
to facilitate escape from the endosome.
Promising tricks for facilitating endosomal 
escape
The most promising ‘tricks’ to overcome entrapment 
include the use of endosomolytic agents, reversible cova-
lent binding and reversible high-affinity non-covalent 
binding. The Pellois group has developed an endoso-
molytic agent to promote release of cargo via endosomal 
leakage. Their dimerized disulfide-linked TAT (dfTAT) can 
destabilize endosomes for the delivery of co-incubated 
cargo (47, 48). This methodology is particularly attrac-
tive as it allows for introduction of cargo, even multiple 
cargos, without direct interaction with TAT. Further, uti-
lization of disulfide bonds should enhance stability for 
systemic delivery.
Another promising method is the use of endosomal 
disruption agents based on antimicrobial peptides (49). 
Using a CPP that also incorporated two membrane-dis-
rupting antimicrobial peptides, investigators were able 
to overcome endosomal entrapment, hypothesizing that 
membrane disruption occurred during vesicular traffick-
ing as the CPP reached the ‘critical membrane disrupting 
concentration’, thus effecting endosomal escape. A fol-
low-on study demonstrated the utility of Salomone et al.’s 
(50) design as a transfection agent with ionically linked 
nucleic acids and CPPs. Other similar efforts to selectively 
disrupt endosomal membranes include engineering of 
‘endosomal escape domains’ (EEDs) (51) and use of pH-
sensitive peptides (23).
Several groups have developed novel reversible 
strategies that may have advantages over endosomolytic 
agents in toxicity, specificity and simplicity. Among the 
reversible strategies, the most common is the use of thiol 
coupling. The reducing environment of both the endo-
some and the cytoplasm should be an effective means to 
reduce disulfides and uncouple cargo from CPP. Further, 
as with the dfTAT model, the use of thiol coupling should 
provide stability and protect the cargo/CPP during sys-
temic delivery. Another approach described by Rossi 
et  al. (52) utilizes an interesting photocleavable linkage 
to deliver cleaved peptides to the cytosol. While this may 
overcome entrapment, this strategy is seemingly imprac-
tical for many applications as it would be difficult to get 
light to many places within patients. The potential of this 
strategy as a research tool, however, may be high.
Models that utilize non-covalent CPP-cargo linkages 
can overcome problems associated with covalently bound 
cargo. Our group has recently described a novel CPP-adap-
tor method that exploits normal ionic gradients to free 
cargo following endosomal entry (53). We associated CPPs 
with their cargos via a reversible coupling between a CPP-
containing calmodulin and cargo that contains a calmo-
dulin binding site (CBS). Our initial findings, described in 
Ref. (53), showed that TAT-fused calmodulin (TAT-CaM) 
bound CBS-containing cargos with nanomolar affinity in 
the presence of calcium but not at all in its absence. In that 
study, three model cargos and three distinct cell lines were 
used, demonstrating general, efficient and rapid delivery 
of cargo to the cytoplasm at a much lower dose (1 μm) 
than necessary using other means. Further, when calcium 
was removed from bound TAT-CaM-cargo complexes, very 
rapid dissociation ensued. As illustrated in Figure 2, the 
high calcium concentrations of the extracellular environ-
ment ensures high-affinity CPP-cargo binding. Following 
entry into the cell, the extracellular calcium is rapidly lost 
as the endosome becomes increasingly acidified (54). We 
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hypothesize that as calcium levels drop, the CPP adaptor 
releases its cargo from the early endosome prior to forma-
tion of the more acidic late endosome.
Considerable attention has been given to the design 
of new, more efficient, delivery mechanisms. The use of 
non-covalent association of CPPs with their cargo is, in 
our opinion, a key strategy to enhance bioavailability of 
biologically active molecules. By non-covalently coupling 
the cargo from the CPP, problems with endosomal entrap-
ment and the potential for a loss of biological activity are 
easily surmountable. Finally, these methodologies typi-
cally require reduced and more therapeutically feasible 
concentrations of protein for the desired effect.
Subcellular localization: targeting freed 
cargo to specific intracellular compartments
Once cargo has been delivered into the cell and success-
fully escaped the endosome, how does the cargo get tar-
geted to a particular location within the cell? Much of 
our understating of subcellular localization of proteins is 
derived from the basic knowledge of signal peptides that 
facilitate localization of proteins to intracellular compart-
ments. Within the endomembrane system, such delivery is 
achieved through sorting of localization signals and sub-
sequent vesicular-mediated targeted delivery. However, 
many subcellular compartments can directly import cyto-
solic proteins provided they contain a specific targeting 
sequence. Such examples include mitochondrial import; 
receptor-mediated nuclear import export; cotranslational 
entry into the ER and import of cytosolic proteins, such 
as catalase, into peroxisomes post-budding off the ER 
membrane.
Protein replacement therapy aims to deliver a fully 
functional protein to replace one that has been mutated, 
lost or is underexpressed. Under ideal circumstances, a 
protein is successfully delivered into the cell, freed from 
the endosome and behaves exactly like a wild-type endog-
enous protein. In the past decade, several groups have 
been successful in this endeavor. A group from the Hebrew 
University-Hadassah Medical School, led by Lorberboum-
Galski et al. (55), has developed and successfully delivered 
functional proteins to the mitochondria in vitro to restore 
defects in the electron-transport chain and acetyl Co-A 
production (56) associated with life-threatening mito-
chondrial diseases. Other groups have also demonstrated 
the ability to deliver functional copies of proteins into 
cells to alleviate dysfunctional proteins associated with 
mitochondrial and lysosomal diseases. For example, in 
2012, Honda et al. (57) were able to deliver functional sub-
units of the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase complex to the cytosol to restore its 
activity ex vivo in neutrophils from patients suffering from 
chronic granulomatous disease (CGD), a disease charac-
terized by improper reactive oxygen species (ROS) produc-
tion resulting from defective NADPH complexes. While 
conceptually simple, these approaches are not without 
significant consideration to ensure the protein will behave 
as it should within the cell. The protein must be produced 
in highly purified, properly folded conformation, have its 
native subcellular localization signal accessible to sub-
cellular import machinery (in the case of non-cytosolic 
proteins), show normal dynamics of stability and activity, 
be expressed at normal endogenous levels, engage with 
binding partners and, in many cases, be able to undergo 
post-translational modification.
Delivery of therapeutic molecules into the cell often 
requires artificial means for intracellular localization of 
the molecule to the compartment of interest. The pre-
dominant approach for targeting CPP-bound cargo calls 
for the fusion of canonical signal sequences to cargo pro-
teins, or even to the CPP tag itself [reviewed in Ref. (58)]. 
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Figure 2: Proposed model for TAT:CaM-mediated intracellular deliv-
ery of CBS:CARGO.
TAT fused with a calmodulin (TAT:CaM) will readily associate with 
cargo containing a calmodulin-binding site (CBS:CARGO) in the 
extracellular environment owing to high levels of calcium (1). Fol-
lowing binding of TAT:CaM to a receptor, an endosome will form 
containing the TAT:CaM-CBS:CARGO as well as high levels of extra-
cellular calcium. As the endosome matures, calcium will be pumped 
out of the intraluminal space while hydrogen ions are brought in (2). 
This shift in calcium concentrations within the endosome will cause 
the CBS:CARGO to disassociate from TAT:CaM, allowing for release 
of the cargo into the cytosol, presumably through ILVs, even if 
TAT:CaM remains tightly bound to its receptor (3). TAT:CaM itself may 
have multiple possible fates following formation of the late endo-
some. It may be sent to the lysosome for degradation if it retains 
its ability to bind its receptor in increasingly acidic conditions (4) or 
sent to the TGN (5) for recycling back to the plasma membrane (6).
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Using this methodology, cargos have been delivered to the 
nucleus (59, 60), the nucleolus (61), the lysosome (62), 
the peroxisome (59), the mitochondria (59, 63, 64) and 
the endoplasmic reticulum (59, 65), to name a few. Draw-
backs to this approach include decreased uptake of tagged 
CPPs (65) and potential endosomal entrapment en route 
to the intended compartment. The underlying mechanism 
via which some of these CPP-cargo complexes gain entry 
into specific subcellular compartments is less well under-
stood. Within the endomembrane system, it is tempting 
to speculate that one might be able to exploit endosomal 
entry for cargo targeting though ensuring proper sorting 
within the late endosome may present challenges.
Targeting CPPs to specific cell types
The specific delivery of cargo to a particular target cell 
or tissue via CPP-mediated methods remains the Holy 
Grail of pharmacological work in this field [reviewed in 
Ref. (66)]. The central problem is that of specificity: given 
that CPP uptake is thought to occur via a general mecha-
nism with a ubiquitous cellular receptor such as HSPGs 
or membrane apparatus, it is extremely facile to deliver 
CPP-tagged cargo proteins systemically. The technical 
challenge, albeit not insurmountable, is to deliver them to 
a particular site, tissue or organ system.
Initial work in this area centered on localized injec-
tion of CPP-tagged cargo proteins. While these approaches 
yield the desired effect of delivery of CPP cargo directly 
to tumor cells, they are only effective for solid, localized 
tumors or easily isolated or discovered target regions.
Other strategies involve exploiting the biochemical 
nature of target cells/tissues. So-called activatable cell-
penetrating peptides (ACPPs) pair technical innovation 
with an improved working knowledge of the affected cel-
lular biochemistry and have been successful with some 
degree of target specificity by several groups [reviewed 
in Ref. (67)]. These ACPPs are activatable in a stimulus-
dependent manner and are caged or masked until they are 
in the vicinity of their target. This methodology employs an 
anionic inhibitor to shield cationic CPPs until they are near 
cells or tissues whose extracellular environment contains 
a product capable of cleaving the anionic inhibitor, thus 
freeing the CPP at a target site. This methodology was suc-
cessfully used in 2004 to target tumor cells by Jiang et al. 
(68) who used a proteolytic cleavage site targeted by metal-
loproteases secreted from tumor cells. These results were 
further confirmed in two reports in 2009 by Olson et  al. 
and Aguilera et  al. of the Tsien group (69, 70). However, 
due to endosomal entrapment (70) and significant 
off-target uptake by other tissues in vivo (71), this techno-
logy has developed primarily as a means to target tumors 
for imaging purposes, which in and of itself has significant 
value.
More recent studies have utilized pH-, photo- and 
hydrogen peroxide-sensitive CPP linkers to target desired 
tissues. In 2014, Weinstain et al. (72) described a hydrogen 
peroxide-sensitive linker that was targeted at lung tissues 
following induction of lipopolysaccharides (LPS)-medi-
ated inflammation in a murine model. Given that infection 
results in high levels of ROS, the constructs would ideally 
only be cleaved in regions undergoing an inflammatory 
response (perhaps cleverly harnessing the endosomal 
entrapment problem in a good way, withholding cargos 
from off-target cell cytoplasms and targeting them for 
destruction!). In 2016, Yang et al. (73) successfully deliv-
ered siRNA in nanoparticles to tumors by exploiting lower 
pH conditions present in those tumors. However, that 
cleavage of the linker relied on both low pH conditions 
and exposure to near IR light confers substantial acces-
sibility limitations. While these studies, and others, yield 
clever and promising targeting mechanisms, they still 
lack the degree of specificity that may be needed for wide-
spread therapeutic application as the potential for off-tar-
get uptake by healthy cells remains a significant concern.
One means of overcoming off-target effects utilizing 
stimulus-dependent methodology is to deliver an ACPP 
that can only be cleaved within targeted cells, provided 
they contain the product needed for cleavage. This so-
called ‘Trojan Horse’ strategy was first employed by 
 Vocero-Abkani et al. (74) in 1999 when the TAT peptide was 
used to deliver procaspase-3 to HIV-infected cells. Here, 
the proteolytic site was replaced by the proteolytic site for 
HIV-1 protease. Upon uptake of the cargo into HIV-infected 
cells, caspase-3 is processed, killing the infected cells (74). 
And while this methodology may have significant thera-
peutic potential, it is certainly limited to specific diseases 
and lacks broader applications.
Perhaps most promisingly, recent biopanning strate-
gies have identified a number of short peptides that confer 
cell-type-specific delivery of cargo proteins via CPP-medi-
ated transduction. Zahid et al. (75) used this approach to 
identify a cardiac-specific peptide, termed cardiac-target-
ing peptide (CTP), which facilitated cargo uptake specifi-
cally to cardiomyocytes following systemic introduction. 
More recently, a cancer-specific CPP was designed by Lim 
et al. (76). This CPP, called BR2, showed enhanced selec-
tivity and nearly a 70% overall increase in cellular uptake 
in cancer cell lines in comparison with normal cells.
When moving from bench to bedside, enhanc-
ing specificity and decreasing off-target effects will be 
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paramount. Considerable attention needs to be given 
to the nature and goal of the treatment and optimiza-
tion of the CPP construct to serve these purposes. What 
has become increasingly clear is that a one-size-fits-all 
model will not be useful in this endeavor. As argued 
above, CPPs that bind ubiquitously expressed mem-
brane proteins will have little promise as to specificity 
without a coincident secondary targeting scheme, such 
as a nanoparticle. However, with significant advances in 
understanding CPP-cell interactions and the biochemical 
nature of afflicted cells of interest, designer therapeutic 
CPPs are clearly on the horizon.
Outlook: cause for optimism
CPPs hold the immense promise of rapid, efficient, non-
toxic delivery of biomolecules into living cells and thus 
represent great hope for development of enabling technol-
ogies for delivering therapeutics now stymied by poor cel-
lular entry. They may also confer other advantages such as 
fine control of dosing as compared to transfection or other 
disruptive delivery method. Technical problems with CPP 
delivery, while significant, may soon be solved with rather 
simple solutions that dissociate cargo from CPP via spon-
taneously cleavable or non-covalent linkages, opening 
the door to new generations of therapeutics. Prospects 
for even further enhanced utility by cell-specific targeting 
and increased ease of coupling, etc. may make them even 
more profoundly effective.
Highlights
 – CPPs can readily enter a variety of cells utilizing mul-
tiple forms of endocytosis and, potentially, via direct 
penetrance.
 – CPP-based technologies are one of the most promis-
ing means for delivery of a wide variety of cargo (pro-
teins, peptides, DNA, siRNAs) into living cells.
 – Endosomal entrapment of CPP-conjugated cargo is a 
limiting factor for the effectiveness of CPPs for protein 
delivery.
 – Current approaches to achieve endosomal escape 
of CPP-associated cargo are destabilization of 
endosomes, the use of cleavable linkers and non-
covalent attachments.
 – Biological CPPs likely enter cells via ubiquitous mech-
anisms; however, designer CPPs are effective at tar-
geting specific cells and tissues.
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